Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Biogen/Eisai’s Aducanumab Fails, Dashing Hopes in Alzheimer’s Field
March 22, 2019
- J-TEC Submits Japan’s First Regenerative Medicine Product in Ophthalmology Field
March 22, 2019
- Mitsubishi Tanabe Sets Up Sales Subsidiary in Malaysia for Independent Marketing
March 22, 2019
- Takeda Taps Neuro-Psychiatric Expert Kajii as T-CiRA Chief
March 22, 2019
- Nippon Shinyaku Licenses Dravet Syndrome Treatment from Zogenix
March 22, 2019
- Chugai, SRL Link Up for Cancer Gene Mutation Tests
March 22, 2019
- Medipal Holdings Invests in Belgium’s Cell Therapy Developer
March 22, 2019
- Gilead Set to Duplicate Biktarvy Success in Japan with New Stand-Alone HIV Sales Force
March 20, 2019
- Daiichi Sankyo’s Edoxaban Demonstrates Efficacy, Safety in AF Patients Undergoing Catheter Ablation
March 20, 2019
- Ono Files Multiple Myeloma Treatment Kyprolis for Once-Weekly Administration Regimen
March 20, 2019
- Servier, Oncodesign Join Forces to Develop Parkinson’s Disease Treatments
March 20, 2019
- NapaJen, Astellas Form Oligonucleotide Research Collaboration
March 19, 2019
- Ono Ties Up with AI Startup twoXAR on Drug Discovery
March 19, 2019
- 9 Month Cost-Effectiveness Analysis Possible If Companies Are Well-Prepared: Crecon Official
March 19, 2019
- Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
- Hitachi Chemical Aspires to World’s No. 1 Regenerative Medicine CMO by Securing Bases in US, Europe through M&As
March 19, 2019
- Entrectinib Filed in Japan for ROS1 Lung Cancer: Chugai
March 18, 2019
- Alfresa Seeks to Expand Foothold in China via Tie-Up with 2nd Largest Drug Wholesaler
March 18, 2019
- Drug Makers, Wholesalers Establishing Supervisory Divisions as Detailing Guidelines Rollout Nears
March 15, 2019
- Synthetic Rubber Form of Rivastach/Exelon Patch Approved: Ono/Novartis
March 15, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…